Navigation Links
InSphero’s New EU Subsidiary Opens for Business
Date:11/26/2013

Schlieren, Switzerland (PRWEB) November 26, 2013

In September 2013, InSphero, a leading supplier of organotypic, biological, in vitro 3D microtissues for highly predictive drug testing based in Switzerland, opened a fully owned subsidiary just over the border in Waldshut, Germany, to cater towards its customers within the European Union. Following the successful launch of the company’s US office back in April, the new European branch aims to serve InSphero’s growing number of customers from the European Union more effectively and expand its EU business, which has always represented an important target market.

The idea of the subsidiary is to speed up the purchasing process and make it easier for InSphero’s customers in the EU. The company’s 3D InSight™ Microtissues and GravityPLUS™ 3D Cell Culture Kits will now be delivered to customers without customs clearance delays and with lower shipping costs than when microtissues were shipped from the InSphero headquarters in Switzerland.

“Our European customers really appreciate the fact that they are now able to obtain our InSphero 3D cell culture products for their assays within twenty-four hours, without them getting held up at customs,” explains Björn Niggemann, Head of Operations at InSphero, who is also responsible for export and distribution and since September has successfully been processing shipments through this new channel with his team. “And apart from anything else, customers also stand to benefit from 15-20% lower shipping costs.”

On the back of all these advantages for the customer, the new office is bound to boost sales this side of the Atlantic.

About InSphero
InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards and is also certified to the ISO 9001:2008 standard for its Quality Management System.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11358275.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Mendel Biotechnology to sell its subsidiary, Mendel Plant Sciences
2. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
3. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
4. New England Biolabs opens seventh subsidiary in Singapore
5. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
6. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
7. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
8. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
9. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
10. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
11. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
Breaking Biology News(10 mins):